Glenmark Pharmaceuticals announced that it has received marketing approval from German authorities for its generic version of Seretide Accuhaler and said that the product will be marketed in Germany as “Salflutin.”
The company acquired development and marketing rights to the fluticasone/salmeterol DPI from Celon for 15 countries, including the UK, Germany, Romania, Denmark, Norway, and Sweden. The DPI was approved in the Nordic countries in 2017, and Glenmark said that the product has been launched in Denmark, Norway, and Sweden.
Glenmark Executive VP and Business Head of Europe and Latin America Achin Gupta commented, “This approval validates Glenmark’s capabilities in the complex inhaled respiratory products segment. Upon launch, generic fluticasone/salmeterol DPI will be Glenmark’s first inhalation product available in Germany. There is huge potential for the product in Germany and we are optimistic that it will help enhance growth of the European business.”
Read the Glenmark Pharmaceuticals press release.
